A phase 1 first-in-human trial of TE-8105 — a novel long-acting GLP-1 receptor agonist — tested four single ascending doses (0.5–3.0 mg) and two multiple-dose regimens in overweight or obese adults without type 2 diabetes. The drug's half-life clocked at approximately 120 hours (five days), nearly double semaglutide's 165-hour half-life but administered subcutaneously every two weeks rather than weekly. In the titration cohort (escalating from 1.5 mg to 3.0 mg Q2W), mean body weight fell 2.06% from baseline, with half of participants achieving ≥5% weight loss. Adverse effects — nausea (up to 21.4%), constipation, vomiting — mirrored the established GLP-1 class profile and were dose-dependent.
The genuine significance here is pharmacokinetic engineering rather than efficacy breakthrough. A biweekly injection schedule could meaningfully improve real-world adherence compared to weekly options like semaglutide or tirzepatide — adherence being a documented Achilles heel of injectable obesity therapy. However, the 2.06% weight reduction is modest compared to semaglutide's 15–17% in phase 3 trials, though direct comparison is premature given this trial's tiny cohort (roughly 8 titration participants), short duration, and sub-therapeutic dose exploration. This is early safety and pharmacokinetic groundwork, not efficacy confirmation. The accumulation ratio of 3.75 for Cmax under titration dosing warrants careful monitoring in longer trials. Incrementally promising, but substantial phase 2 data on weight outcomes at higher sustained doses is needed before assessing competitive differentiation.
